Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BI 1839100 in healthy men
NL-OMON60775Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of BI 1839100, sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started Sep 2024; status: completed.
02
Drugs
BI 1839100
Beyond the preview
Go deeper on NL-OMON60775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60775.